PRAME by IHC

Alphabetical Test listing

PRAME by IHC-12376 - Technical only, 12379 - Technical & interpretation

  
PRAME by IHC
  
12376 - Technical only, 12379 - Technical & interpretation
  
LAB12376
LAB12379
  
Preferentially expressed antigen in melanoma
  
All IHC stains will include a positive control tissue
  
  • To distinguish metastatic melanoma in lymph nodes from nodal nevi
  • To distinguish melanoma from a subset of nevi

PRAME positivity is based on the percentage of cells staining. A 0-4 point staining scale is used. 4+ staining is defined as ≥ 75% of cells staining. PRAME is typically interpreted in conjunction with another melanocytic immunohistochemical stain.

  
Tissue
  

Submit a formalin-fixed, paraffin embedded tissue block

  

Formalin-fixed, paraffin embedded (FFPE) tissue block

  

FFPE tissue section mounted on a charged, unstained slide

  

Ambient (preferred)

  
  • Unlabeled/mislabeled block
  • Insufficient tissue
  • Slides broken beyond repair
  
AHL- Immunohistochemistry
  
Mo - Fr
  
1-2 days
  

Immunohistochemical staining and microscopic examination

  

If requested, an interpretive report will be provided

  

Specifications

  • PRAME is positive in multiple epithelial tumors, seminomas, sarcomas, and melanoma. Normal tissues positive for PRAME: Testis, proliferative endometrium. PRAME clone EPR20330 stains normal sebaceous glands.
  • PRAME positive epithelial tumors include: Sebaceous carcinomas, basal cell carcinoma, breast carcinoma, pulmonary nonsmall cell carcinoma,  ENT squamous cell carcinoma, renal cell carcinoma, clear cell carcinoma, endometrial carcinoma, uterine serous carcinoma, uterine carcinosarcoma, ovarian clear cell carcinoma, adenoid cystic carcinoma, thymic carcinoma, seminoma.
  • PRAME positive sarcomas/neuroectodermal tumors include: Synovial sarcoma, myxoid liposarcoma, neuroblastoma. 

Staining pattern

  • Nuclear
  • Cytoplasmic can be seen in non-melanocytic tumors

References

  1. Gradecki et al. PRAME expression in 155 cases of metastatic melanoma. J Cutan Pathol 2021;48;479-485.
  2. Lezcano C et al. PRAME expression in melanocytic tumors. Am J Surg Pathol 2018;42(11):1456-1465.
  3. Kaczorowski M et al. PRAME expression in cancer. A systemic immunohistochemical study of >5800 epithelial and nonepithelial tumors. Am J Surg Pathol 2022;46(11):1467-1476.

 

  
88342 - 1st stain
88341 - each additional stain
  
09/21/2023